Which has better valuation & earnings, AIDX or KPLT?

Katapult has higher revenue and earnings than 20/20 Biolabs. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio 20/20 Biolabs $1.84M 3.52 N/A N/A N/A Katapult $291.76M 0.11 $1.37M $1.15 5.66

Is AIDX or KPLT more profitable?

Katapult has a net margin of 2.48% compared to 20/20 Biolabs' net margin of 0.00%. 20/20 Biolabs' return on equity of 0.00% beat Katapult's return on equity. Company Net Margins Return on Equity Return on Assets 20/20 Biolabs N/A N/A N/A Katapult 2.48% -16.24% 7.63%

Which has preferable earnings & valuation, AIDX or XBP?

XBP Global has higher revenue and earnings than 20/20 Biolabs. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio 20/20 Biolabs $1.84M 3.52 N/A N/A N/A XBP Global $791.04M 0.04 $1.10B -$3.28 N/A

Is AIDX or XBP more profitable?

XBP Global has a net margin of 130.26% compared to 20/20 Biolabs' net margin of 0.00%. XBP Global's return on equity of 1,645.47% beat 20/20 Biolabs' return on equity. Company Net Margins Return on Equity Return on Assets 20/20 Biolabs N/A N/A N/A XBP Global 130.26% 1,645.47% 146.77%

Which has preferable earnings and valuation, AIDX or CAST?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio 20/20 Biolabs $1.84M 3.52 N/A N/A N/A FreeCast (Direct Listing) $565.17K 274.90 N/A N/A N/A

Is AIDX or CAST more profitable?

Company Net Margins Return on Equity Return on Assets 20/20 Biolabs N/A N/A N/A FreeCast (Direct Listing) N/A N/A N/A

Do analysts prefer AIDX or GRNQ?

20/20 Biolabs presently has a consensus price target of $5.00, suggesting a potential upside of 716.99%. Given 20/20 Biolabs' stronger consensus rating and higher probable upside, analysts plainly believe 20/20 Biolabs is more favorable than Greenpro Capital. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score 20/20 Biolabs 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Greenpro Capital 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better valuation and earnings, AIDX or GRNQ?

20/20 Biolabs has higher earnings, but lower revenue than Greenpro Capital. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio 20/20 Biolabs $1.84M 3.52 N/A N/A N/A Greenpro Capital $2.07M 12.06 -$2.98M -$0.39 N/A

Which has higher earnings & valuation, AIDX or ARAI?

20/20 Biolabs has higher revenue and earnings than Arrive AI. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio 20/20 Biolabs $1.84M 3.52 N/A N/A N/A Arrive AI $110K 232.90 -$12.83M -$0.52 N/A

20/20 Biolabs (AIDX) Competitors

$0.61 -0.35 (-36.43%)

As of 02:27 PM Eastern

Compare

AIDX vs. KPLT, XBP, CAST, GRNQ, and ARAI

Should you buy 20/20 Biolabs stock or one of its competitors? MarketBeat compares 20/20 Biolabs with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with 20/20 Biolabs include Katapult (KPLT), XBP Global (XBP), FreeCast (Direct Listing) (CAST), Greenpro Capital (GRNQ), and Arrive AI (ARAI). These companies are all part of the "business services" industry.

How does 20/20 Biolabs compare to Katapult?

20/20 Biolabs (NASDAQ:AIDX) and Katapult (NASDAQ:KPLT) are both small-cap business services companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability and risk.

Katapult has higher revenue and earnings than 20/20 Biolabs.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
20/20 Biolabs	$1.84M	3.52	N/A	N/A	N/A
Katapult	$291.76M	0.11	$1.37M	$1.15	5.66

26.8% of Katapult shares are owned by institutional investors. 8.0% of Katapult shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Katapult has a net margin of 2.48% compared to 20/20 Biolabs' net margin of 0.00%. 20/20 Biolabs' return on equity of 0.00% beat Katapult's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
20/20 Biolabs	N/A	N/A	N/A
Katapult	2.48%	-16.24%	7.63%

20/20 Biolabs presently has a consensus price target of $5.00, indicating a potential upside of 716.99%. Katapult has a consensus price target of $10.00, indicating a potential upside of 53.52%. Given 20/20 Biolabs' stronger consensus rating and higher probable upside, equities research analysts clearly believe 20/20 Biolabs is more favorable than Katapult.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
20/20 Biolabs	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Katapult	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

In the previous week, Katapult had 1 more articles in the media than 20/20 Biolabs. MarketBeat recorded 3 mentions for Katapult and 2 mentions for 20/20 Biolabs. Katapult's average media sentiment score of 0.65 beat 20/20 Biolabs' score of 0.44 indicating that Katapult is being referred to more favorably in the news media.

Company	Overall Sentiment
20/20 Biolabs	Neutral
Katapult	Positive

Summary

Katapult beats 20/20 Biolabs on 7 of the 12 factors compared between the two stocks.

How does 20/20 Biolabs compare to XBP Global?

20/20 Biolabs (NASDAQ:AIDX) and XBP Global (NASDAQ:XBP) are both small-cap business services companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, profitability, media sentiment, earnings, analyst recommendations and dividends.

XBP Global has a net margin of 130.26% compared to 20/20 Biolabs' net margin of 0.00%. XBP Global's return on equity of 1,645.47% beat 20/20 Biolabs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
20/20 Biolabs	N/A	N/A	N/A
XBP Global	130.26%	1,645.47%	146.77%

In the previous week, 20/20 Biolabs and 20/20 Biolabs both had 2 articles in the media. XBP Global's average media sentiment score of 1.44 beat 20/20 Biolabs' score of 0.44 indicating that XBP Global is being referred to more favorably in the news media.

Company	Overall Sentiment
20/20 Biolabs	Neutral
XBP Global	Positive

15.7% of XBP Global shares are owned by institutional investors. 31.4% of XBP Global shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

20/20 Biolabs currently has a consensus target price of $5.00, suggesting a potential upside of 716.99%. XBP Global has a consensus target price of $5.00, suggesting a potential upside of 97.63%. Given 20/20 Biolabs' higher probable upside, research analysts clearly believe 20/20 Biolabs is more favorable than XBP Global.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
20/20 Biolabs	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
XBP Global	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

XBP Global has higher revenue and earnings than 20/20 Biolabs.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
20/20 Biolabs	$1.84M	3.52	N/A	N/A	N/A
XBP Global	$791.04M	0.04	$1.10B	-$3.28	N/A

Summary

XBP Global beats 20/20 Biolabs on 7 of the 9 factors compared between the two stocks.

How does 20/20 Biolabs compare to FreeCast (Direct Listing)?

20/20 Biolabs (NASDAQ:AIDX) and FreeCast (Direct Listing) (NASDAQ:CAST) are both small-cap services companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, risk, profitability, analyst recommendations, institutional ownership and media sentiment.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
20/20 Biolabs	$1.84M	3.52	N/A	N/A	N/A
FreeCast (Direct Listing)	$565.17K	274.90	N/A	N/A	N/A

0.0% of FreeCast (Direct Listing) shares are owned by institutional investors. 17.5% of FreeCast (Direct Listing) shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

20/20 Biolabs currently has a consensus price target of $5.00, indicating a potential upside of 716.99%. FreeCast (Direct Listing) has a consensus price target of $6.00, indicating a potential upside of 59.66%. Given 20/20 Biolabs' higher possible upside, analysts plainly believe 20/20 Biolabs is more favorable than FreeCast (Direct Listing).

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
20/20 Biolabs	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
FreeCast (Direct Listing)	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, FreeCast (Direct Listing) had 21 more articles in the media than 20/20 Biolabs. MarketBeat recorded 23 mentions for FreeCast (Direct Listing) and 2 mentions for 20/20 Biolabs. 20/20 Biolabs' average media sentiment score of 0.44 beat FreeCast (Direct Listing)'s score of 0.20 indicating that 20/20 Biolabs is being referred to more favorably in the media.

Company	Overall Sentiment
20/20 Biolabs	Neutral
FreeCast (Direct Listing)	Neutral

Company	Net Margins	Return on Equity	Return on Assets
20/20 Biolabs	N/A	N/A	N/A
FreeCast (Direct Listing)	N/A	N/A	N/A

Summary

FreeCast (Direct Listing) beats 20/20 Biolabs on 4 of the 7 factors compared between the two stocks.

How does 20/20 Biolabs compare to Greenpro Capital?

20/20 Biolabs (NASDAQ:AIDX) and Greenpro Capital (NASDAQ:GRNQ) are both small-cap business services companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, institutional ownership, dividends, media sentiment and earnings.

In the previous week, 20/20 Biolabs had 1 more articles in the media than Greenpro Capital. MarketBeat recorded 2 mentions for 20/20 Biolabs and 1 mentions for Greenpro Capital. Greenpro Capital's average media sentiment score of 0.93 beat 20/20 Biolabs' score of 0.44 indicating that Greenpro Capital is being referred to more favorably in the news media.

Company	Overall Sentiment
20/20 Biolabs	Neutral
Greenpro Capital	Positive

0.9% of Greenpro Capital shares are owned by institutional investors. 39.7% of Greenpro Capital shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

20/20 Biolabs presently has a consensus price target of $5.00, suggesting a potential upside of 716.99%. Given 20/20 Biolabs' stronger consensus rating and higher probable upside, analysts plainly believe 20/20 Biolabs is more favorable than Greenpro Capital.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
20/20 Biolabs	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Greenpro Capital	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

20/20 Biolabs has higher earnings, but lower revenue than Greenpro Capital.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
20/20 Biolabs	$1.84M	3.52	N/A	N/A	N/A
Greenpro Capital	$2.07M	12.06	-$2.98M	-$0.39	N/A

20/20 Biolabs has a net margin of 0.00% compared to Greenpro Capital's net margin of -153.32%. 20/20 Biolabs' return on equity of 0.00% beat Greenpro Capital's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
20/20 Biolabs	N/A	N/A	N/A
Greenpro Capital	-153.32%	-31.13%	-25.47%

Summary

20/20 Biolabs beats Greenpro Capital on 7 of the 12 factors compared between the two stocks.

How does 20/20 Biolabs compare to Arrive AI?

20/20 Biolabs (NASDAQ:AIDX) and Arrive AI (NASDAQ:ARAI) are both small-cap business services companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, valuation, risk, media sentiment and profitability.

20/20 Biolabs has higher revenue and earnings than Arrive AI.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
20/20 Biolabs	$1.84M	3.52	N/A	N/A	N/A
Arrive AI	$110K	232.90	-$12.83M	-$0.52	N/A

In the previous week, 20/20 Biolabs and 20/20 Biolabs both had 2 articles in the media. Arrive AI's average media sentiment score of 1.71 beat 20/20 Biolabs' score of 0.44 indicating that Arrive AI is being referred to more favorably in the news media.

Company	Overall Sentiment
20/20 Biolabs	Neutral
Arrive AI	Very Positive

20/20 Biolabs currently has a consensus price target of $5.00, suggesting a potential upside of 716.99%. Arrive AI has a consensus price target of $12.00, suggesting a potential upside of 2,329.15%. Given Arrive AI's higher possible upside, analysts clearly believe Arrive AI is more favorable than 20/20 Biolabs.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
20/20 Biolabs	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Arrive AI	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

20/20 Biolabs has a net margin of 0.00% compared to Arrive AI's net margin of -13,348.06%. 20/20 Biolabs' return on equity of 0.00% beat Arrive AI's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
20/20 Biolabs	N/A	N/A	N/A
Arrive AI	-13,348.06%	-0.95%	-0.50%

Summary

20/20 Biolabs beats Arrive AI on 4 of the 7 factors compared between the two stocks.

Get 20/20 Biolabs News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AIDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AIDX vs. The Competition

Export

Metric	20/20 Biolabs	Services – Research, Development, Testing Labs Industry	Services Sector	NASDAQ Exchange
Market Cap	$6.50M	$8.95M	$977.91M	$12.37B
Dividend Yield	N/A	N/A	4.70%	5.66%
P/E Ratio	N/A	N/A	11.33	24.65
Price / Sales	3.52	2.51	42.13	167.03
Price / Cash	N/A	N/A	55.62	37.92
Price / Book	N/A	0.30	11.69	6.81
Net Income	N/A	-$15.16M	-$12.34M	$337.32M
7 Day Performance	-27.14%	-14.43%	11.46%	2.37%
1 Month Performance	-54.33%	-17.02%	5.31%	4.25%
1 Year Performance	N/A	N/A	102.99%	32.60%

20/20 Biolabs Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AIDX 20/20 Biolabs	N/A	$0.61 -36.4%	$5.00 +717.0%	N/A	$6.50M	$1.84M	N/A	14	Gap Down High Trading Volume
KPLT Katapult	2.7333 of 5 stars	$6.13 -0.3%	$10.00 +63.1%	-35.4%	$29.79M	$291.76M	5.43	130
XBP XBP Global	4.2578 of 5 stars	$2.49 +4.2%	$5.00 +100.8%	-75.3%	$29.31M	$791.04M	N/A	10,600	Positive News Short Interest Decrease Gap Down
CAST FreeCast (Direct Listing)	4.1206 of 5 stars	$0.70 +2.7%	$6.00 +762.1%	N/A	$28.82M	$565.17K	N/A	48	Gap Up
GRNQ Greenpro Capital	1.1217 of 5 stars	$1.55 +1.0%	N/A	-14.6%	$27.86M	$2.13M	N/A	60	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AIDX) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

20/20 Biolabs (AIDX) Competitors

AIDX vs. KPLT, XBP, CAST, GRNQ, and ARAI

How does 20/20 Biolabs compare to Katapult?

Summary

How does 20/20 Biolabs compare to XBP Global?

Summary

How does 20/20 Biolabs compare to FreeCast (Direct Listing)?

Summary

How does 20/20 Biolabs compare to Greenpro Capital?

Summary

How does 20/20 Biolabs compare to Arrive AI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AIDX vs. The Competition

20/20 Biolabs Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

20/20 Biolabs (AIDX) Competitors

AIDX vs. KPLT, XBP, CAST, GRNQ, and ARAI

How does 20/20 Biolabs compare to Katapult?

Which has better valuation & earnings, AIDX or KPLT?

Do insiders and institutionals believe in AIDX or KPLT?

Is AIDX or KPLT more profitable?

Do analysts recommend AIDX or KPLT?

Does the media favor AIDX or KPLT?

Summary

How does 20/20 Biolabs compare to XBP Global?

Is AIDX or XBP more profitable?

Does the media prefer AIDX or XBP?

Do insiders and institutionals hold more shares of AIDX or XBP?

Do analysts rate AIDX or XBP?

Which has preferable earnings & valuation, AIDX or XBP?

Summary

How does 20/20 Biolabs compare to FreeCast (Direct Listing)?

Which has preferable earnings and valuation, AIDX or CAST?

Do institutionals and insiders believe in AIDX or CAST?

Do analysts rate AIDX or CAST?

Does the media refer more to AIDX or CAST?

Is AIDX or CAST more profitable?

Summary

How does 20/20 Biolabs compare to Greenpro Capital?

Does the media refer more to AIDX or GRNQ?

Do institutionals & insiders hold more shares of AIDX or GRNQ?

Do analysts prefer AIDX or GRNQ?

Which has better valuation and earnings, AIDX or GRNQ?

Is AIDX or GRNQ more profitable?

Summary

How does 20/20 Biolabs compare to Arrive AI?

Which has higher earnings & valuation, AIDX or ARAI?

Does the media favor AIDX or ARAI?

Do analysts rate AIDX or ARAI?

Is AIDX or ARAI more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AIDX vs. The Competition

20/20 Biolabs Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools